As previously reported, Deutsche Bank upgraded Argenx (ARGX) to Buy from Hold with a price target of EUR 725, up from EUR 675. Despite a “somewhat underwhelming” Q4 report on February 26, the firm sees the valuation as “no longer as demanding as it was previously” and notes that Vyvgart commercial momentum is “looking intact overall” and that Argenx is now consistently profitable.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARGX:
- Argenx Opens Phase 1 Safety Trial for ARGX-124, Expanding Its Pipeline Potential
- Argenx Unveils New VYVGART and Neurology Pipeline Data Ahead of 2026 AAN Meeting
- Argenx Earnings Call Highlights Explosive Growth, Ocular Win
- Argenx price target lowered to $890 from $925 at RBC Capital
- Argenx price target raised to $867 from $858 at Baird